Several PLK2 inhibitorshave been developed in recent years., In cancertherapy, the pan-PLK inhibitor BI-2536 has completed phaseII evaluation and has demonstrated antiproliferative activity acrossvarious solid tumors. In addition, compoundsC2 and C21 suppress cancer cell growth, and compound 7AO (ON1231320) induces mitotic arrest and apoptosis,highlighting their therapeutic potential., However,most of these compounds exhibit limited selectivity. The gene discussed is PLK2; the disease is cancer.